Display options
Cite
Coluccio C, Begini P, Marzano A, et al. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017;9(25):1043-1053doi: 10.4254/wjh.v9.i25.1043.
Coluccio, C., Begini, P., Marzano, A., Pellicelli, A., Imperatrice, B., Anania, G., Delle Fave, G., & Marignani, M. (2017). Hepatitis B in patients with hematological diseases: An update. World journal of hepatology, 9(25), 1043-1053. https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio, Chiara, et al. "Hepatitis B in patients with hematological diseases: An update." World journal of hepatology vol. 9,25 (2017): 1043-1053. doi: https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043. PMID: 28951776; PMCID: PMC5596311.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043.

Hepatitis B in patients with hematological diseases: An update.

World journal of hepatology

Chiara Coluccio, Paola Begini, Alfredo Marzano, Adriano Pellicelli, Barbara Imperatrice, Giulia Anania, Gianfranco Delle Fave, Massimo Marignani

Affiliations

  1. Digestive and Liver Diseases Department, Sant'Andrea Hospital, School of Medicine and Psychology, Sapienza University, 00189 Rome, Italy. [email protected].
  2. Digestive and Liver Diseases Department, Sant'Andrea Hospital, School of Medicine and Psychology, Sapienza University, 00189 Rome, Italy.
  3. Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, 10126 Turin, Italy.
  4. Liver Unit, San Camillo Forlanini Hospital, 00152 Rome, Italy.

PMID: 28951776 PMCID: PMC5596311 DOI: 10.4254/wjh.v9.i25.1043

Abstract

Hepatitis B virus (HBV) reactivation (HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immunosuppressed patients. Aim of this paper is to provide a critical review of the relevant information emerged in the recent literature regarding HBV reactivation following immunosuppressive treatments for oncohematological tumors. A computerized literature search in MEDLINE was performed using appropriate terms arrangement, including English-written literature only or additional relevant articles. Articles published only in abstract form and case reports not giving considerable news were excluded. Clinical manifestation of HBVr can be manifold, ranging from asymptomatic self-limiting anicteric hepatitis to life-threatening fulminant liver failure. In clusters of patients adverse outcomes are potentially predictable. Clinicians should be aware of the inherent risk of HBVr among the different virological categories (active carriers, occult HBV carriers and inactive carriers, the most intriguing category), and classes of immunosuppressive drugs. We recommend that patients undergoing immunosuppressive treatments for hematological malignancies should undergo HBV screening. In case of serological sign(s) of current or past infection with the virus, appropriate therapeutic or preventive strategies are suggested, according to both virological categories, risk of HBVr by immunosuppressive drugs and liver status. Either antiviral drug management and surveillance and pre-emptive approach are examined, commenting the current international recommendations about this debated issue.

Keywords: Chemotherapy; Entecavir; Hematology; Hepatitis B virus; Immunosuppressive therapy; Lamivudine; Lymphoma; Occult/active/inactive carrier; Prophylaxis; Reactivation

Conflict of interest statement

Conflict-of-interest statement: The authors have no disclosures to report.

References

  1. Gastroenterology. 1991 Jan;100(1):182-8 - PubMed
  2. Gastroenterology. 2015 Jan;148(1):221-244.e3 - PubMed
  3. Br J Cancer. 2004 Apr 5;90(7):1306-11 - PubMed
  4. Hepatology. 2016 Aug;64(2):381-9 - PubMed
  5. J Viral Hepat. 2015 Oct;22(10):842-9 - PubMed
  6. N Engl J Med. 2014 Mar 13;370(11):1008-18 - PubMed
  7. J Clin Oncol. 2015 Jul 1;33(19):2212-20 - PubMed
  8. Hepatology. 2008 Mar;47(3):844-53 - PubMed
  9. Clin Mol Hepatol. 2016 Jun;22(2):219-37 - PubMed
  10. Clin Gastroenterol Hepatol. 2016 Oct;14 (10 ):1481-1489.e5 - PubMed
  11. Ann Intern Med. 2008 Apr 1;148(7):519-28 - PubMed
  12. Oncotarget. 2016 May 24;7(21):30642-58 - PubMed
  13. Gut. 2012 May;61(5):641-5 - PubMed
  14. Hepatol Int. 2016 Jan;10 (1):1-98 - PubMed
  15. J Clin Oncol. 2013 Aug 1;31(22):2765-72 - PubMed
  16. Gastroenterology. 2010 Aug;139(2):483-90 - PubMed
  17. J Clin Oncol. 2009 Feb 1;27(4):605-11 - PubMed
  18. Br J Haematol. 2002 Jan;116(1):166-9 - PubMed
  19. Hepatology. 1986 Mar-Apr;6(2):173-9 - PubMed
  20. Blood. 2002 Apr 1;99(7):2324-30 - PubMed
  21. Hepatology. 2009 Sep;50(3):661-2 - PubMed
  22. Haematologica. 2006 Apr;91(4):554-7 - PubMed
  23. Hepatology. 2006 Feb;43(2):233-40 - PubMed
  24. Hepatology. 2003 Jun;37(6):1320-8 - PubMed
  25. N Engl J Med. 2014 Jun 12;370(24):2352-4 - PubMed
  26. Dig Liver Dis. 2007 May;39(5):397-408 - PubMed
  27. Blood Rev. 2013 May;27(3):155-64 - PubMed
  28. Semin Liver Dis. 2013 May;33(2):167-77 - PubMed
  29. N Engl J Med. 2014 Mar 20;370(12):1101-10 - PubMed
  30. Hepatology. 2008 Nov;48(5):1451-9 - PubMed
  31. Clin Infect Dis. 2011 Jun;52(11):1294-306 - PubMed
  32. Ann Hematol. 2010 Mar;89(3):255-62 - PubMed
  33. Expert Opin Biol Ther. 2012 Mar;12(3):343-51 - PubMed
  34. J Hepatol. 2012 Jul;57(1):167-85 - PubMed
  35. PLoS One. 2015 May 14;10(5):e0126037 - PubMed
  36. PLoS One. 2015 Jun 29;10(6):e0131545 - PubMed
  37. Gastroenterology. 2017 May;152(6):1297-1309 - PubMed
  38. N Engl J Med. 2006 Mar 9;354(10):1001-10 - PubMed
  39. JAMA. 2014 Dec 17;312(23):2521-30 - PubMed
  40. Ann Oncol. 2011 May;22(5):1170-80 - PubMed
  41. Cell Mol Immunol. 2015 May;12(3):309-16 - PubMed
  42. J Hepatol. 2008 Oct;49(4):652-7 - PubMed
  43. Liver Int. 2017 Mar;37(3):362-368 - PubMed
  44. World J Gastroenterol. 2016 Jul 28;22(28):6484-500 - PubMed
  45. Virology. 1988 Dec;167(2):630-3 - PubMed
  46. N Engl J Med. 2006 Mar 9;354(10):1011-20 - PubMed
  47. Breast Cancer Res Treat. 2011 Jun;127(3):705-12 - PubMed
  48. MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20 - PubMed
  49. Gastroenterology. 2003 Dec;125(6):1742-9 - PubMed
  50. J Hepatol. 2017 Aug;67(2):370-398 - PubMed
  51. Liver Int. 2008 Jan;28(1):28-38 - PubMed

Publication Types